leuprolide acetate for depot suspension / Generic mfg. 
Welcome,         Profile    Billing    Logout  
 138 Diseases   93 Trials   93 Trials   2194 News 


«12345678910111213...3334»
  • ||||||||||  Erleada (apalutamide) / J&J
    THE ENCROACHING LESION: A CASE OF AN ENDOBRONCHIAL PROSTATE CANCER METASTASES (Convention Center Exhibit Hall: Poster Area 3) -  Sep 11, 2024 - Abstract #CHEST2024CHEST_6605;    
    Although exceedingly rare, endobronchial lesions can represent the initial presentation of metastatic non-pulmonary malignancies. Furthermore, this case highlights how robotic-assisted navigational bronchoscopy offers a promising avenue for obtaining precise biopsies of small sub-cm pulmonary lesions.
  • ||||||||||  carboplatin / Generic mfg., leuprolide acetate for depot suspension / Generic mfg., paclitaxel / Generic mfg.
    THORACIC SMARCA4-DEFICIENT UNDIFFERENTIATED TUMOR: A CASE REPORT WITH MOLECULAR ANALYSIS (Convention Center 257 AB) -  Sep 11, 2024 - Abstract #CHEST2024CHEST_6098;    
    Thoracic SMARCA4-UT is a newly recognized aggressive thoracic malignancy and clinical awareness of this entity is necessary for early diagnosis. Further studies exploring immunotherapy and other targeted treatment options are needed.
  • ||||||||||  Firmagon (degarelix) / Astellas, Ferring, Orgovyx (relugolix) / Intas, Gedeon Richter, Takeda, ASKA Pharma, Sumitomo Pharma, Pfizer
    Journal:  Testosterone recovery after androgen deprivation therapy. (Pubmed Central) -  Sep 7, 2024   
    GnRH antagonist use and younger age are associated with higher rates of T recovery after ADT. Longer ADT courses were associated with worse T recovery rates.
  • ||||||||||  leuprolide acetate for depot suspension / Generic mfg., bicalutamide / Generic mfg., docetaxel / Generic mfg.
    Random Rectal Biopsies Unveiling Prostate Adenocarcinoma in Ulcerative Colitis After Previous Radical Prostatectomy (Exhibit Hall E) -  Aug 20, 2024 - Abstract #ACG2024ACG_4253;    
    Despite the recommendation for chemotherapy with Taxotere, the patient expressed a preference to explore antiandrogen therapy now...Biopsy remains the gold standard for diagnosis, especially in cases with unusual clinical features and concurrent inflammatory bowel disease. Treatment approaches for prostate cancer vary from case to case and may include chemotherapy, radiation, surgery, and in some cases hormone therapy with close monitoring.
  • ||||||||||  leuprolide acetate for depot suspension / Generic mfg., norethindrone / Generic mfg.
    Ectopic Tissue Causing Hematochezia - A Monthly Saga (Exhibit Hall E) -  Aug 20, 2024 - Abstract #ACG2024ACG_2601;    
    Figure: Figure 1. A 7 cm colonic mass proximal to the proximal Houston valve, extending from 23 cm to 16 cm, occupying about 50 % of the lumen, firm, with nodular and friable surface.
  • ||||||||||  leuprolide acetate for depot suspension / Generic mfg., tamoxifen / Generic mfg., paclitaxel / Generic mfg.
    Identifying Resource Needs of Patients with Breast Cancer by Examining Alignment of Reddit Post Content with BREAST-Q Domains (201-204_Level 2_South; In Person Only) -  Aug 9, 2024 - Abstract #ACSCLINCON2024ACS_CLINCON_1049;    
    The results underscore the crucial significance of continuous surveillance and meticulous monitoring to promptly identify and manage AEs, ultimately enhancing patient safety and well-being while undergoing leuprorelin therapy. Allergic to the Taxol which caused pneumonitis?Neuropathy in both hands and feet...So much muscle and joint pain that I can't sit too long, can't stand too long, can't walk more than a couple of blocks.
  • ||||||||||  Erleada (apalutamide) / J&J, Firmagon (degarelix) / Astellas, Ferring
    Trial completion date, Trial primary completion date:  PRESTO: A Study of Androgen Annihilation in High-Risk Biochemically Relapsed Prostate Cancer (clinicaltrials.gov) -  Aug 7, 2024   
    P3,  N=504, Active, not recruiting, 
    Allergic to the Taxol which caused pneumonitis?Neuropathy in both hands and feet...So much muscle and joint pain that I can't sit too long, can't stand too long, can't walk more than a couple of blocks. Trial completion date: Jan 2025 --> Jan 2026 | Trial primary completion date: Jul 2024 --> Jul 2025
  • ||||||||||  leuprolide acetate for depot suspension / Generic mfg.
    Journal:  Prostatic Utricle Cysts as a Potential Pitfall in PSMA PET/CT Interpretation. (Pubmed Central) -  Aug 5, 2024   
    The patient then received intensity-modulated radiotherapy directed to 2 PSMA-avid pelvic nodes and leuprolide acetate, achieving an undetectable PSA in 4 months. This case highlights a potential pitfall in PSMA PET interpretation associated with prostatic utricle cysts.
  • ||||||||||  leuprolide acetate for depot suspension / Generic mfg.
    RECURRENT CATAMENIAL PNEUMOTHORAX: AN ILLUSTRATIVE CASE REPORT (Convention Center Exhibit Hall: Poster Area 3) -  Jul 31, 2024 - Abstract #CHEST2024CHEST_2810;    
    Multidisciplinary team involvement and a high index of suspicion are required to make the diagnosis. Multi-modal treatment with pleurodesis and hormonal suppression improves pneumothorax rate, but recurrence is common.
  • ||||||||||  Ibrance (palbociclib) / Pfizer
    IT'S NOT A ''MET!'': METACHRONOUS EYE CARCINOMA ON PREVIOUSLY METASTATIC BREAST CANCER (Convention Center Exhibit Hall: Poster Area 2) -  Jul 31, 2024 - Abstract #CHEST2024CHEST_2665;    
    Healthcare providers must monitor survivors of cancer for the potential development of MPM. Discussing follow-up plans and lifestyle modifications becomes essential to mitigate these risks and enhance the overall well-being of cancer survivors.
  • ||||||||||  leuprolide acetate for depot suspension / Generic mfg.
    A BREATH OF KNOWLEDGE: A CASE REPORT OF THORACIC ENDOMETRIOSIS SYNDROME (Convention Center Exhibit Hall: Rapid Fire Area 3D) -  Jul 31, 2024 - Abstract #CHEST2024CHEST_1980;    
    While VATS is the definitive diagnostic tool, negative pathology does not exclude TES, as observed in this case. Management entails hormonal suppressive therapy to mitigate recurrence risk, given the difficulty in eradicating thoracic endometrial implants.
  • ||||||||||  Xtandi (enzalutamide capsule) / Pfizer, Astellas, Nubeqa (darolutamide) / Bayer, Orion Corp, Erleada (apalutamide) / J&J
    METASTATIC PROSTATE ADENOCARCINOMA PRESENTING WITH ACUTE HYPOXIC RESPIRATOR FAILURE: A RARE PRESENTATION. (Convention Center Exhibit Hall: Poster Area 3) -  Jul 31, 2024 - Abstract #CHEST2024CHEST_1622;    
    Metastatic prostate adenocarcinoma presenting with hypoxic respiratory failure poses diagnostic and therapeutic challenges. Prompt recognition and appropriate management are crucial for optimizing patient outcomes.
  • ||||||||||  Enrollment closed, Trial completion date, Trial primary completion date:  First Strike, Second Strike Therapies for High Risk Metastatic Castration Sensitive Prostate Cancer (clinicaltrials.gov) -  Jul 22, 2024   
    P2,  N=32, Active, not recruiting, 
    EAU-HRBCR criteria identified pts in whom ENZ ( Recruiting --> Active, not recruiting | Trial completion date: Jan 2027 --> Jul 2028 | Trial primary completion date: Jan 2027 --> Jul 2027
  • ||||||||||  thalidomide / Generic mfg.
    EFFECTS OF THALIDOMIDE IN THE TREATMENT OF EXPERIMENTAL ENDOMETRIOSIS IN RATS (Exhibition Hall/Poster Area) -  Jul 18, 2024 - Abstract #IASP2024IASP_2750;    
    In FET cycles, leuprorelin (as a GnRHa) downregulation combined with HRT may improve the clinical outcome of patients compared to the HRT cycle, especially for the clinical pregnancy and embryo implantation rates of patients with blastocyst transfer. In the model studied, thalidomide had ananalgesic, anti-inflammatory action and reduced the size of the implants, more significantlywith doses starting at 50 mg/kg/day, and can be suggested as an option in the treatment ofendometriosis pain.
  • ||||||||||  Opdivo (nivolumab) / BMS
    Trial primary completion date:  Nivolumab + Docetaxel + ADT in mHSPC Patients With DDRD or Inflamed Tumors (clinicaltrials.gov) -  Jul 17, 2024   
    P2,  N=60, Active, not recruiting, 
    In the model studied, thalidomide had ananalgesic, anti-inflammatory action and reduced the size of the implants, more significantlywith doses starting at 50 mg/kg/day, and can be suggested as an option in the treatment ofendometriosis pain. Trial primary completion date: Jun 2024 --> Dec 2024
  • ||||||||||  Firmagon (degarelix) / Astellas, Ferring
    Review, Journal, Metastases:  Front-Line Therapeutic Strategy in Metastatic Hormone Sensitive Prostate Cancer: An Updated Therapeutic Algorithm. (Pubmed Central) -  Jun 17, 2024   
    LHRH antagonists, such as degarelix, have also emerged...This review outlines pivotal trials leading to drug approvals in mHSPC and proposes a treatment decision algorithm for the same, based on statement from the Tuscan Interdisciplinary Uro-Oncological Group. A multidisciplinary approach is crucial to tailor treatment intensity and weigh risks and benefits effectively.
  • ||||||||||  Yervoy (ipilimumab) / BMS
    Phase classification:  Neoadjuvant Ipilimumab in Prostate Cancer (clinicaltrials.gov) -  Jun 6, 2024   
    P2,  N=19, Completed, 
    More attention should be given to monitoring for CPP during long-term follow-up of craniopharyngiomas in the clinic. Phase classification: P2a --> P2
  • ||||||||||  Herceptin (trastuzumab) / Roche, Kisqali (ribociclib) / Novartis, Perjeta (pertuzumab) / Roche
    Enrollment closed, Trial completion date, Trial primary completion date:  Detect V / CHEVENDO (Chemo vs. Endo) (clinicaltrials.gov) -  Jun 3, 2024   
    P3,  N=271, Active, not recruiting, 
    Not yet recruiting --> Recruiting | Trial completion date: Nov 2027 --> Aug 2027 | Trial primary completion date: Nov 2026 --> May 2027 Recruiting --> Active, not recruiting | Trial completion date: Nov 2024 --> Jan 2025 | Trial primary completion date: Sep 2024 --> Jan 2025
  • ||||||||||  Orgovyx (relugolix) / Intas, Gedeon Richter, Takeda, ASKA Pharma, Sumitomo Pharma, Pfizer
    Enrollment closed, Trial completion date, Trial primary completion date:  REVELUTION: RElugolix VErsus LeUprolide Cardiac Trial (clinicaltrials.gov) -  Jun 3, 2024   
    P4,  N=93, Active, not recruiting, 
    The findings suggest that cardiovascular adverse events associated with GnRHa may be related to age and other underlying physiopathological conditions rather than the drug. Recruiting --> Active, not recruiting | Trial completion date: Apr 2025 --> Jan 2026 | Trial primary completion date: Apr 2024 --> Jan 2025
  • ||||||||||  leuprolide acetate for depot suspension / Generic mfg.
    Infertility resolved after proper thoracic assessment: A case of disseminated endometriosis (PS-18; Poster board no. 19) -  May 31, 2024 - Abstract #ERS2024ERS_2325;    
    Gynecology started Leuprolide therapy...This case underscores the challenges of diagnosing and managing extra-pelvic endometriosis, emphasizing the need for a multidisciplinary approach. The patient's eventual pregnancy highlights the importance of timely and comprehensive management for complex endometriosis cases.
  • ||||||||||  leuprolide acetate for depot suspension / Generic mfg.
    Journal:  A pediatric case of two Nicolau syndrome lesions following leuprolide injection in the upper extremity. (Pubmed Central) -  May 29, 2024   
    The fact that the development of NS cannot be detected in advance and the risk of rapid progression of tissue necrosis make disease management difficult. The prognosis of NS significantly depends on the patient, and when a developing lesion is noticed early, it is crucial to minimize the risk of complications.
  • ||||||||||  sunitinib / Generic mfg.
    Trial completion date, Trial primary completion date:  Sunitinib Malate With Hormonal Ablation for Patients Who Will Have Prostatectomy (clinicaltrials.gov) -  May 23, 2024   
    P2,  N=64, Active, not recruiting, 
    Real-world evidence will be collected in a clinical setting to use pre-treatment with an oral gonadotropin-releasing hormone antagonist to reduce intraoperative bleeding in women who undergo laparoscopic myomectomy. Trial completion date: Dec 2024 --> Dec 2025 | Trial primary completion date: Dec 2024 --> Dec 2025